Medication Abortion Via Pharmacy Dispensing

Improving access to and efficiency of abortion provision is important for patients and
providers. The Risk Evaluation and Mitigation Strategy (REMS) requires that Mifeprex ® (
mifepristone) be dispensed only from a doctor's office, clinic or hospital (not from a
pharmacy by prescription) by a certified health care provider and the health care provider
must obtained a signed Patient Agreement Form before dispensing mifepristone. Data are needed
to investigate the feasibility, acceptability, and effectiveness of pharmacy dispensing of
mifepristone. In order to address the study question, a mixed methods study design is
appropriate. To assess feasibility, the study will collect data on pharmacists' satisfaction
with dispensing mifepristone. To assess acceptability, qualitative data will be collected
from pharmacists about their perspectives on dispensing Mifeprex before and after the study,
as well as measure patient satisfaction through open-ended and close-ended survey questions.
To assess effectiveness of the pharmacy dispensing model, the study will evaluate clinical
outcomes from electronic health records. The proposed feasibility study would take place at
sites in California and Washington states.

Patient Inclusion Criteria:

- Women seeking medication abortion through 70 days gestation

- Eligible for Mifeprex® at a study clinical site

- English or Spanish speaking

- Willing and able to participate in the study, including willing to go to the study
pharmacy to obtain mifepristone

Patient Exclusion Criteria:

- Not pregnant

- Not seeking medication abortion

- Under the age of 15

- Contraindications for medication abortion

- All pharmacists providing services at one of the study pharmacies during the
study are eligible for the pharmacist survey and interview.